晚期大肠癌的个体化治疗精选.pptVIP

MCH-2 v4 10-24-06 SUMMARY Targeted therapies have improved clinical outcome of mCRC Need judicious use of these agents: when, how Many questions remaining How to overcome the high cost ? Treatments need to be individualized: biomarkers and genetic signatures Story for GI at ASCO 2008 1st biomarker for individualized therapy for colorectal cancer: KRAS status predicts responsiveness (or lack of responsiveness) to EGFR targeted therapies Advances in the Treatment of Colorectal Cancer BOND 1: Randomized Pivotal Trial in Metastatic Colorectal Cancer Cetuximab Randomized Pivotal Trial: Response